HC Wainwright assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note released on Friday. The firm issued a buy rating and a $75.00 target price on the biotechnology company’s stock.

SRPT has been the subject of a number of other research reports. Goldman Sachs Group reiterated a buy rating and issued a $71.00 price target on shares of Sarepta Therapeutics in a report on Friday, October 6th. ValuEngine lowered Sarepta Therapeutics from a hold rating to a sell rating in a report on Monday, October 2nd. Oppenheimer reiterated a buy rating on shares of Sarepta Therapeutics in a report on Monday, September 25th. SunTrust Banks restated a buy rating and set a $56.00 target price on shares of Sarepta Therapeutics in a report on Thursday, September 7th. Finally, Robert W. Baird restated a buy rating and set a $101.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, October 17th. One analyst has rated the stock with a sell rating, six have issued a hold rating and seventeen have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $64.14.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down $0.42 during midday trading on Friday, hitting $55.25. The company had a trading volume of 1,713,742 shares, compared to its average volume of 1,778,143. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. Sarepta Therapeutics has a 12-month low of $26.26 and a 12-month high of $57.57.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.66. The firm had revenue of $45.95 million during the quarter, compared to analyst estimates of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same quarter in the previous year, the business earned ($0.95) earnings per share. analysts anticipate that Sarepta Therapeutics will post -3.11 EPS for the current year.

In other Sarepta Therapeutics news, CEO Douglas S. Ingram purchased 38,138 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average cost of $52.44 per share, with a total value of $1,999,956.72. Following the completion of the transaction, the chief executive officer now owns 420,196 shares in the company, valued at approximately $22,035,078.24. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Shamim Ruff sold 11,500 shares of the company’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $50.00, for a total value of $575,000.00. The disclosure for this sale can be found here. Corporate insiders own 9.60% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. increased its position in shares of Sarepta Therapeutics by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 271 shares in the last quarter. Cubist Systematic Strategies LLC increased its position in shares of Sarepta Therapeutics by 116.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after acquiring an additional 2,474 shares during the period. Edge Wealth Management LLC acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter valued at $175,000. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Sarepta Therapeutics by 140.9% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 2,493 shares during the period. Finally, Fox Run Management L.L.C. acquired a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at $204,000. 82.02% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.watchlistnews.com/sarepta-therapeutics-srpt-now-covered-by-analysts-at-hc-wainwright/1739824.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.